Philips extends RESP offer deadline
This article was originally published in Clinica
Philips has moved the expiration date of its offer for Respironics shares to March 6. The original deadline for the offer had been February 4, but this was extended to February 22. On expiration of the second deadline, the Dutch electronics group said it had acquired 63.7 million - or 82% - of outstanding Respironics shares. In December 2007, Philips agreed to buy the Murrysville, Pennsylvania-based home healthcare and respiratory device specialist for $66 per share (see Clinica No 1288, p 1).
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.